BMI (kg/m2) 　 <23, n (%) 23–25, n (%) ≥25, n (%) p value 177 (40.7)

Slides:

Advertisements

Similar presentations

1 times table 2 times table 3 times table 4 times table 5 times table

Advertisements

 Genes are found on the X AND Y chromosomes.  Genes that are carried on the sex chromosomes are called sex linked genes.

Routine screening tests Hai Ho, M.D.. Most expensive part of medical practice? Your Pen.

UofT GU Oncology, 2004 CLINICAL CASES. UofT GU Oncology, y.o. female  Familiar history: Thyroid cancer (mother) Prostate cancer (father)  PMH:

Insulin Resistance Progression to Diabetes. Hypertension: BP >140/90 Dyslipidemia: ◦TG >150 mg/dL (1.7 mmol.L) ◦HDL-C

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

$100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300 $400 $500 $100 $200 $300.

Tables Learning Support

Lots of funny looking graphs. Age distribution Dependency ratio: number of people who are too young/old to work compared to the number of productive.

Table S1. CD44 expression and clinicopathologic characteristics Cases (n=54) CD44 protein expression P value* Negativ e WeakStrong (n=8)(n=23) Age

Males Females © Crown copyright and database rights 2012 Ordnance Survey Adult obesity: BMI ≥ 30kg/m 2.

親愛的吉姆舅舅：今天吃完晚餐後，奶奶說，在家裡情況變好以前，您要我搬到城裡跟您住。奶奶有沒有跟您說，爸爸已經好久沒有工作，也好久沒有人請媽媽做衣服了？我們聽完都哭了，連爸爸也哭了，但是媽媽說了一個故事讓我們又笑了。她說：您們小的時候，她曾經被您追得爬到樹上去，真的嗎？雖然我個子小，但是我很強壯，

10/3/2014. Εμφραγμα - Στηθαγχη - Πονος στο στηθος : Εμφραγμα μυοκαρδιου λεμε την βαρυτατη εκεινη κατασταση που οφειλεται στην αποφραξη που μπορει να γινει.

Lung Cancer in Never-Smokers from the Princess Margaret Cancer Centre 1 Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada;

Table 2. Characteristics of Study Patients

CCO Independent Conference Highlights

Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

LYMPHADENECTOMY IN UROTHELIAL CARCINOMA IN THE RENAL PELVIS AND URETER

Volume 60, Issue 5, Pages (November 2011)

Insert Footer or Copyright Information Here

Number of brain metastasis

CCO Independent Conference Highlights

A new preoperative Severity Scoring System For Acute Cholecystitis

EXPRESSION OF ABERRANT p53 PROTEIN IN GASTRIC CANCER

NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma

TUMOR PD-L1 TIL PD-L1 TUMOR & TIL PD-L1 Age Low High P value R Pearson

Fig. 4. First-line treatment according to 2014 KLCSG-NCC Korea Practice Guidelines for patients with HCC, Child-Pugh class A, no portal hypertension, and.

Additional Figure 1: Hazard ratios of ER-positive and ER-negative tumors for increased BMI across 5-year age-bands. All models are for a 5 kg/m2 increase.

Body Mass Index, Sex, and Cardiovascular Disease Risk Factors Among Hispanic/Latino Adults: Hispanic Community Health Study/Study of Latinos by Robert.

Correlation Between the International Consensus Definition of the Cancer Anorexia- Cachexia Syndrome (CACS) and Patient-Centered Outcomes in Advanced Non-Small.

ارزیابی وضعیت تغذیه ای Assessment of Nutritional Status

Two Way ANOVAs Factorial Designs.

CHAPTER 7 Nutritional Status on Dialysis

Preoperative Nutritional Deficiency Is a Useful Predictor of Postoperative Outcome in Patients Undergoing Curative Resection for Gastric Cancer Xuechao.

Differences in Performance Status Assessment Among Palliative Care Specialists, Nurses, and Medical Oncologists Yu Jung Kim, MD, PhD, David Hui, MD,

A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma Yirui Zhai, MD, Zhouguang Hui, MD, Wei Ji, MD, Xiaozhen Wang,

MILTARY PAY TABLES 2018.

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

EVALUATE EFFECTIVENESS OF GEFIITINIB IN FIRST LINE TREATIMENT AVANCED NSCLC PATIENTS WITH EGFR MUTATION BS TRẦN THỊ CHUNG, Ths. NGUYỄN THỊ OANH Oncology.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

!'!!. = pt >pt > \ ___,..___,..

Does Karnofsky Performance Status of Patients With Cirrhosis on the Transplant Waitlist Meet the Eyeball Test? Elliot B. Tapper, MD Clinical Gastroenterology.

OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.

The Microscope.

First-Line Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer with Poor Performance Status Young Joo Lee, MD, Heung Tae Kim, MD,

Determining Sex.

Aberrant Wnt1/β-Catenin Expression is an Independent Poor Prognostic Marker of Non- small Cell Lung Cancer After Surgery Xianhua Xu, MD, Ping-Li Sun,

A B D C Total adiponectin (μg/ml ) Hb ( g / dl ) r = p = 0.003

Wolfgang Sieghart, Florian Hucke, Markus Peck-Radosavljevic

Does Liver Regeneration Increase the Postoperative HCC Recurrence after Curative Resection ? Jin-Ho Lee, MD. Department of Surgery, Yonsei University.

Leora Horn, MD, MSc, FRCPC, Alan B. Sandler, MD, Joe B

Clinical Characteristics and Atheroma Burden of Subjects at Baseline Stratified According to Gender Nicholls SJ. et al. J Am Coll Cardiol 2007;49:

MILTARY PAY TABLES 2019.

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results.

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Forest plots for all drugs (OS and PFS HRs combined): excellent versus reduced PS comparison and ECOG PS levels comparison (see online supplementary 1). ECOG.

Correlation of change in H2 concentration (△H2) haemodynamics or laboratory parameters. Correlation of change in H2 concentration (△H2) haemodynamics or.

3 times tables.

6 times tables.

Correlation between plasma C reactive protein (CRP) and angiopoietin-like protein 4 (ANGPTL4). Correlation between plasma C reactive protein (CRP) and.

Supplementary Table S2 Correlation between pre-operative plasma miR-451 or miR-486 concentrations and clinicopathologic features in gastric cancer patients.

1. What animal 2. Male or Female ? 4. Male or Female? Why? Why?

Evaluation of E–R (AEs-DC/D) in NSCLC in the full model using (A) estimated covariate effects and (B) VPCs. For continuous variables in the covariate analysis,

OS by OR for the Sorafenib plus HAIC Group

Circulating serum inflammatory markers, a) neutrophils, b) platelets, c) fibrinogen and d) C-reactive protein (CRP), in patients with chronic airflow obstruction.

Patient disposition over the 52-week study period

Fig. 2. HR estimated by the multivariate analysis for predicting factors associated with longer overall survival using a Cox regression model at the time.

Receiver operating characteristic (ROC) curve analysis for the LENT score and Eastern Cooperative Oncology Group (ECOG) performance score (PS) for the.

Presentation transcript:

Appendix Table 2. The association between BMI and clinicopathological factors BMI (kg/m2) 　 <23, n (%) 23–25, n (%) ≥25, n (%) p value 177 (40.7) 124 (28.5) 134 (30.8) sex male 112 (63.3) 99 (79.8) 107 (79.9) 0.001 female 65 (36.7) 25 (20.2) 27 (20.1) presentation incidental 115 (65.0) 94 (75.8) 106 (79.1) 0.013 symptomatic 62 (35.0) 30 (24.2) 28 (20.9) pT stage 1 118 (66.7) 83 (66.9) 104 (77.6) 0.222 2 21 (11.9) 10 (8.1) 12 (9.0) 3 35 (19.8) 17 (12.7) 4 3 (1.6) 1 (0.8) 1 (0.7) pN stage 0 or x 171 (96.6) 119 (96.0) 131 (97.8) 0.707 positive 6 (4.4) 5 (4.0) 3 (2.2) M stage 158 (89.3) 108 (87.1) 125 (93.3) 0.242 19 (10.7) 16 (12.9) 9 (6.7) nephrectomy type partial 23 (13.0) 17 (13.7) 21 (15.7) 0.792 total 154 (87.0) 107 (86.3) 113 (84.3) nuclear grade ≤2 130 (73.5) 92 (74.2) 117 (87.3) 0.007 ≥3 47 (26.5) 32 (25.8) MVI negative 134 (75.5) 96 (77.4) 115 (85.8) 0.077 43 (24.3) 28 (22.6) 19 (14.2) ECOG-PS 159 (89.8) 112 (90.3) 128 (95.5) 0.156 ≥1 18 (10.2) 12 (9.7) 6 (4.5) CRP <0.3 mg/dl 125 (70.6) 79 (63.7) 105 (78.4) 0.034 ≥0.3 mg/dl 51 (29.4) 45 (36.3) 29 (21.6) MVI, microscopic venous invasion ECOG-PS, Eastern Cooperative Oncology Group Performance Status; CRP, C-reactive protein